-+ 0.00%
-+ 0.00%
-+ 0.00%
According to the North China Pharmaceutical announcement, a total of 240 varieties of the company and its subsidiaries were included in the 2026 edition of the national medical insurance catalogue, including 113 in category A and 127 in category B. No products were transferred this time. Seven new varieties have been selected, including a class of innovative drugs olumutevir injection, tacrolimus capsules, cefuprofen tablets, lettemovir injections, roxastat capsules, edoxaban toluene sulfonate tablets, and nadroparin calcium injections. The total sales revenue of the newly included products mentioned above is 170 million yuan in 2025, and the total sales revenue for the 1st to 3rd quarter of 2026 is 121 million yuan. This inclusion will have a positive impact on product market expansion, and it is not expected to have a significant impact on business performance in the short term.
Share
Listen to the news
According to the North China Pharmaceutical announcement, a total of 240 varieties of the company and its subsidiaries were included in the 2026 edition of the national medical insurance catalogue, including 113 in category A and 127 in category B. No products were transferred this time. Seven new varieties have been selected, including a class of innovative drugs olumutevir injection, tacrolimus capsules, cefuprofen tablets, lettemovir injections, roxastat capsules, edoxaban toluene sulfonate tablets, and nadroparin calcium injections. The total sales revenue of the newly included products mentioned above is 170 million yuan in 2025, and the total sales revenue for the 1st to 3rd quarter of 2026 is 121 million yuan. This inclusion will have a positive impact on product market expansion, and it is not expected to have a significant impact on business performance in the short term.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending